Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001679 · ClinicalTrials.gov registry record
Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients
A clinical trial of Arthritis, Rheumatoid and Synovitis, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- Completed
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT00001679 is a study of Arthritis, Rheumatoid and Synovitis that has completed, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The registered enrollment target is 250 participants, below the 632-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00001679, a study of Arthritis, Rheumatoid and Synovitis, has completed, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- COMPLETED
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the 2-5 year outcome of a cohort of 250 patients with early synovitis, who were recruited into protocol 94-AR-0194 (The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis). Clinical, radiographic, and functional outcome parameters, particularly those relating to articular damage and functional loss, will be evaluated and related back to clinical, serologic, immunogenetic, and pathologic variables identified at the onset of the arthropathy. A model will be generated which incorporates and weighs the variables in order to determine diagnostic and prognostic markers in the early stages of arthritis. Synovial tissue samples have been obtained from the entire cohort at the initial visit of protocol 94-AR-0194. Studies of these biopsies have so far demonstrated evidence for the presence of infectious agents in a proportion of the samples, and have generated information regarding the cytokine profiles in the early stages of synovitis. In an attempt to further define the pathogenetic mechanisms of synovitis longitudinally, biopsies will be repeated on selected subsets of the cohort. Specific questions to be answered relate to the persistence of microbial agents in the synovium, and to the evolution of cellular and molecular mechanisms which mediate the invasive, destructive potential of the synovial lesion. It is anticipated that these studies should prove valuable to clinicians who are attempting to stratify patients for therapeutic strategies, early in their disease course. They should also prove valuable in enhancing the understanding of the pathogenetic mechanisms of synovitis.
Conditions Studied
Study Locations (1)
Maryland
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 1998-08 |
| Est. Completion | 2000-06 |
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)93 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001679
The ClinicalTrials.gov registry entry for NCT00001679 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 632-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (60% lower). The listed sponsor is National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 0 interventions.
NCT00001679 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001679 about?
NCT00001679 is a clinical study titled "Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients". This study will evaluate the 2-5 year outcome of a cohort of 250 patients with early synovitis, who were recruited into protocol 94-AR-0194 (The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis). Clinical, radiographic, and functional outcome parameters, particularly those relating...
What is the current status of trial NCT00001679?
This trial is currently completed. The enrollment target is 250 participants. The study started on 1998-08. Estimated completion is 2000-06.
What conditions does trial NCT00001679 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid, Synovitis, Arthritis, Reactive.
Who is sponsoring clinical trial NCT00001679?
This trial is sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001679 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chronic Pain in Rheumatoid Arthritis
RECRUITING
-
R-2487 in Patients With Rheumatoid Arthritis
RECRUITING · Phase 1
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
-
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
RECRUITING · Phase 2
-
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
RECRUITING
-
INFINITY™ With ADAPTIS™ Technology Study
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.